Blackstone Life Sciences announced that it will lead a $350 million royalty and equity investment in Reata Pharmaceuticals as it works on a potential therapy for a rare Alport . . .
Continue Reading With a Free Trial
Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.
Already a subscriber? Log in.